TY - JOUR
T1 - First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings
AU - MacMillan, Margaret L.
AU - Hippen, Keli L.
AU - McKenna, David H.
AU - Kadidlo, Diane
AU - Sumstad, Darin
AU - Defor, Todd E.
AU - Brunstein, Claudio G.
AU - Holtan, Shernan G.
AU - Miller, Jeffrey S.
AU - Warlick, Erica D.
AU - Weisdorf, Daniel J.
AU - Wagner, John E.
AU - Blazar, Bruce R.
N1 - Publisher Copyright:
© 2021 by The American Society of Hematology.
PY - 2021/3/9
Y1 - 2021/3/9
N2 - Human CD41252 T cells cultured in interleukin 2 (IL-2), rapamycin, and transforming growth factor b (TGFb) along with anti-CD3 monoclonal antibody-loaded artificial antigenpresenting cells generate FoxP31 induced regulatory T cells (iTregs) with potent suppressive function. We performed a phase 1, single-center, dose-escalation study to determine the safety profile of iTregs in adults with high-risk malignancy treated with reduced-intensity conditioning and mobilized peripheral blood stem cells (PBSCs) from HLA-identical sibling donors. Sixteen patients were enrolled and 14 were treated (2 productions failed to meet desired doses). One patient each received 3.0 3 106/kg, 3.0 3 107/kg, and 3.0 3 108/kg iTregs with corresponding T-conventional-to-iTreg ratios of 86:1, 8:1, and 1:2. After 3 patients received 3.0 3 108/kg in the presence of cyclosporine (CSA) and mycophenolate mofetil (MMF) with no dose-limiting toxicities, subsequent patients were to receive iTregs in the presence of sirolimus/MMF that favors Foxp3 stability based on preclinical modeling. However, 2 of 2 developed grade 3 acute graft-versus-host disease (GVHD), resulting in suspension of the sirolimus/MMF. An additional 7 patients received 3.0 3 108/kg iTregs with CSA/MMF. In the 14 patients treated with iTregs and CSA/MMF, there were no severe infusional toxicities with all achieving neutrophil recovery (median, day 13). Of 10 patients who received 3.0 3 108/kg iTregs and CSA/MMF, 7 had no aGVHD, 2 had grade 2, and 1 had grade 3. Circulating Foxp31 iTregs were detectable through day 14. In summary, iTregs in the context of CSA/MMF can be delivered safely at doses as high as 3 3 108/kg. This trial was registered at www.clinicaltrials.gov
AB - Human CD41252 T cells cultured in interleukin 2 (IL-2), rapamycin, and transforming growth factor b (TGFb) along with anti-CD3 monoclonal antibody-loaded artificial antigenpresenting cells generate FoxP31 induced regulatory T cells (iTregs) with potent suppressive function. We performed a phase 1, single-center, dose-escalation study to determine the safety profile of iTregs in adults with high-risk malignancy treated with reduced-intensity conditioning and mobilized peripheral blood stem cells (PBSCs) from HLA-identical sibling donors. Sixteen patients were enrolled and 14 were treated (2 productions failed to meet desired doses). One patient each received 3.0 3 106/kg, 3.0 3 107/kg, and 3.0 3 108/kg iTregs with corresponding T-conventional-to-iTreg ratios of 86:1, 8:1, and 1:2. After 3 patients received 3.0 3 108/kg in the presence of cyclosporine (CSA) and mycophenolate mofetil (MMF) with no dose-limiting toxicities, subsequent patients were to receive iTregs in the presence of sirolimus/MMF that favors Foxp3 stability based on preclinical modeling. However, 2 of 2 developed grade 3 acute graft-versus-host disease (GVHD), resulting in suspension of the sirolimus/MMF. An additional 7 patients received 3.0 3 108/kg iTregs with CSA/MMF. In the 14 patients treated with iTregs and CSA/MMF, there were no severe infusional toxicities with all achieving neutrophil recovery (median, day 13). Of 10 patients who received 3.0 3 108/kg iTregs and CSA/MMF, 7 had no aGVHD, 2 had grade 2, and 1 had grade 3. Circulating Foxp31 iTregs were detectable through day 14. In summary, iTregs in the context of CSA/MMF can be delivered safely at doses as high as 3 3 108/kg. This trial was registered at www.clinicaltrials.gov
UR - http://www.scopus.com/inward/record.url?scp=85103474257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103474257&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2020003219
DO - 10.1182/bloodadvances.2020003219
M3 - Article
C2 - 33666654
AN - SCOPUS:85103474257
SN - 2473-9529
VL - 5
SP - 1425
EP - 1436
JO - Blood Advances
JF - Blood Advances
IS - 5
ER -